Aptevo Therapeutics Inc. (APVO) Stock: New Financing Targets $4.5M in Gross Proceeds

TLDR

• Aptevo targets $4.5 million through warrant exercises and a private placement.
• Existing warrant holders will exercise up to 254,922 shares at $4.03 per share.
• The PIPE offers up to 861,708 shares plus warrants covering 4.3 million shares.
• Aptevo expects both financing transactions to close around August 13, 2026.
• Net proceeds will support working capital as Aptevo advances its cancer pipeline.

Aptevo Therapeutics stock traded near $4.14, up about 0.50%, on Wednesday as the company unveiled a new financing package. The transactions target about $4.5 million in gross proceeds through warrant exercises and a separate private placement. Aptevo plans to direct the net proceeds toward working capital as it continues developing its cancer treatment pipeline.

Aptevo Therapeutics Inc., APVO

Aptevo Warrant Exercises Add Fresh Capital

Aptevo reached inducement agreements with holders of existing warrants covering up to 254,922 common shares. Those holders agreed to exercise the warrants for cash at a reduced price of $4.03 per share. In return, Aptevo will issue new unregistered warrants covering up to 1,274,610 shares at the same exercise price.

The new inducement warrants will require stockholder approval before holders can begin exercising them. Once exercisable, those warrants will remain outstanding for five years from their initial exercise date. Effective SEC registration statements cover shares produced through the existing warrant exercises.

Roth Capital Partners serves as the exclusive placement agent for the warrant inducement and private placement transactions. Aptevo expects the transactions to close around August 13, subject to customary closing conditions. The planned closing would provide fresh operating funds as Aptevo advances clinical and preclinical oncology programs.

PIPE Financing Expands Share and Warrant Offering

Separately, Aptevo agreed to sell up to 861,708 unregistered common shares through a private placement transaction. The company priced those shares at $4.03 each, matching the reduced exercise price for the existing warrants. Purchasers can instead select pre-funded warrants when required to remain within specified beneficial ownership limits.

The financing also includes common warrants allowing purchasers to acquire up to 4,308,540 additional Aptevo shares. These common warrants carry a $4.03 exercise price and also require stockholder approval before exercise. They will expire five years after their initial exercise date, while pre-funded warrants remain exercisable immediately.

Aptevo offered the private securities under exemptions from registration requirements within the Securities Act of 1933. However, the company agreed to file a registration statement covering future resale of specified shares and warrant shares. That filing will cover securities linked to the inducement warrants, private placement, pre-funded warrants, and common warrants.

Aptevo Financing Supports Oncology Development

Aptevo operates as a clinical-stage biotechnology company focused on multispecific immunotherapies for cancer treatment. Its lead candidate, mipletamig, targets frontline acute myeloid leukemia alongside venetoclax and azacitidine. The program forms part of a broader pipeline spanning blood cancers and solid tumors.

Aptevo develops its pipeline through proprietary platforms that support bispecific and trispecific therapeutic candidates. Those programs include APVO451, a preclinical candidate targeting nectin-4 in solid tumors. The company also explores radiopharmaceutical opportunities that could extend its tumor-targeting work into additional treatment approaches.

The new capital raise adds working capital while Aptevo continues funding research, clinical development, and corporate operations. Earlier SEC filings showed recurring operating losses and negative operating cash flow, highlighting the importance of financing access.The latest transactions expand near-term funding while creating additional warrant-linked share issuance if holders exercise later.

The post Aptevo Therapeutics Inc. (APVO) Stock: New Financing Targets $4.5M in Gross Proceeds appeared first on Blockonomi.